Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

Innovus Pharmaceuticals, Inc. (INNV)

Add INNV Price Alert      Hide Sticky   Hide Intro
Moderator: BooDog, kkpennies, John Kent, NewTrader2017
Search This Board: 
Last Post: 11/20/2017 9:01:59 PM - Followers: 134 - Board type: Free - Posts Today: 51
* shareholders, please consider purchasing product(s)


Awaiting Official Announcement of FDA Approval for FlutiCare

FlutiCare Approval could bring a BILLION DOLLARS in sales annually

REDONDO BEACH, CA--(Marketwired - Jul 12, 2016) -, a leading financial news and information portal offering free real time public company filing alerts, discusses the potential impact of the anticipated FDA ruling on Innovus Pharmaceuticals' (OTCQB: INNV) ANDA filing for FlutiCare™, the company's over-the-counter treatment for allergic rhinitis.

FlutiCare™ is designed to treat non-allergic rhinitis -- better known as "hay fever" or "stuffy nose" -- which affects roughly 50 million Americans each year. While 70% of these individuals use over-the-counter products, more than half are not satisfied with the treatment option, according to an Asthma and Allergy Foundation of America survey, which suggests there's an opportunity for a prescription-strength OTC treatment option to capture market share from category leaders.

As the #1 prescription nasal steroid with over 177 million units sold since 2007, Innovus believes that the over-the-counter version of FlutiCare™ could be worth up to $1 billion per year by addressing a much wider over-the-counter market. The FDA decision is expected in the next several weeks.


The CEO has already signed an agreement for the manufacturing of FlutiCare

Innovus Pharma Achieves Major Milestone With Securing a Manufacturing Agreement for FlutiCare in Anticipation of the FDA Decision

SAN DIEGO, CA--(Marketwired - May 31, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced that it signed a manufacturing agreement for the supply of its FlutiCare™ 60 and 120 spray/bottles.  Innovus signed the agreement in anticipation of the FDA's decision, expected between July-September of this year, on the ANDA application for the drug.


Prior to joining Innovus Pharma,

Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. 
where he helped move the company's stock price from
19 Cents to $6.00 !!!
(Uplisted from OTC to NASDAQ)


Company Profile:

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

Business Summary:

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The company?s pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was incorporated in 2011 and is based in San Diego, California.

Bassam Damaj, Ph.D.
President and Chief Executive Officer:

Dr. Bassam Damaj was appointed to serve as our President and Chief Executive Officer in January 2013. Prior to joining Innovus Pharma, Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company, from December 2009 until November 2012. At Apricus Bio, Dr. Damaj was responsible for the approval of its lead drug Vitaros, a treatment for erectile dysfunction. Dr. Damaj also signed multimillion dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. Before Apricus Bio, Dr. Damaj was a co-founder of Bio-Quant, Inc. and served as the Chief Executive Officer and Chief Scientific Officer and a Director of Bio-Quant's board of directors from its inception in June 2000 until its acquisition by Apricus Biosciences in December 2009. In addition, Dr. Damaj was the founder, Chairman, President and Chief Executive Officer of R&D Healthcare, and the co-founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was a Member of the Scientific Advisory Board of MicroIslet, Inc. He is the author of the Immunological Reagents and Solutions reference book, the inventor of many patents and author of numerous peer reviewed scientific publications. Dr. Damaj won a US Congressional award for the Anthrax Multiplex Diagnostic Test in 2003. Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University.

Who are the major players at Innovus Pharma?


Share Structure:

Shares Outstanding:     150.5 Million (as of 4/28/17)   Dr. Damaj owns $23.7M shares.  Novalere owns 25.6M.  One person and One Entity own ~ 32.8% of the outstanding shares. 

Profitability expected exiting Q4 2017 !
- 2017 Projected Revenue of $15M (NOT counting FlutiCare), which would be approximately 3x GREATER than 2016. 


Company Videos:

Innovus Pharma CEO Provides Shareholder Update and Conference Call

Corporate Presentation November 2016 (8-K  11/1/2016)

Upcoming PDUFA and ANDA Approval Dates Could Catalyze Innovus Pharma (INNV) and Lipocine (LPCN)

Innovus Pharma (INNV): Targeting $3+ Billion Markets With 13 Commercial Products

Major 2016 Accomplishments:



Where can INNV products be seen?


Existing Product Lines @ Innovus Pharma:

Newest Product:


PROSTAGORX™ is a clinical strength, multi response prostate supplement, scientifically formulated to effectively maintain good prostate health and help in prevent prostate issues in the future. ProstaGorx™ was developed by top medical doctors and produced in a top-quality, cGMP certified and FDA registered laboratory environment under the most rigorously professional conditions. 

The positive benefits provided by the individual and combination ingredients in ProstaGorx™ have been published in leading medical journals.


Are you looking to boost your brain health?r

** Help to get the word out and be a PRODUCT AMBASSADOR for YOUR company

Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
INNV News: Quarterly Report (10-q) 11/14/2017 04:41:42 PM
INNV News: Current Report Filing (8-k) 11/14/2017 04:24:20 PM
INNV News: Current Report Filing (8-k) 11/14/2017 06:13:49 AM
INNV News: Statement of Changes in Beneficial Ownership (4) 10/02/2017 04:57:33 PM
INNV News: Statement of Changes in Beneficial Ownership (4) 10/02/2017 04:56:09 PM
#12430  Sticky Note !!! $INNV Investor Starter Guide !!!! John Kent 11/20/17 10:31:19 AM
#11803  Sticky Note $19B market. I think I'd be loading up BooDog 10/03/17 06:04:18 AM
#11037  Sticky Note Innovus Pharma Orders its First Commercial Batch of kkpennies 08/09/17 02:44:19 PM
#12475   I agree due for a big pop$ STOCK-WIZ 11/20/17 09:01:59 PM
#12474   Tomorrow is gonna go boom! Termiteous 11/20/17 08:58:57 PM
#12473   INNV looks like a solid winner from current level$ STOCK-WIZ 11/20/17 08:50:47 PM
#12472   He didn't post the other day either when Mwilson1 11/20/17 08:18:28 PM
#12471   From INNV CEO" John Kent 11/20/17 06:44:12 PM
#12470   The chart I posted is based on U.S John Kent 11/20/17 06:29:49 PM
#12469   Thanks for that info! INNV Bull$hark 11/20/17 06:29:45 PM
#12467   Why hasn't TwistedFreak been on here and posting today? gi197845 11/20/17 06:22:56 PM
#12466   Wish I knew the secrets :) gi197845 11/20/17 06:21:38 PM
#12465   I sure hope Dr.Damaj isn't over promising with gi197845 11/20/17 06:20:55 PM
#12464   R U sure? Bull$hark 11/20/17 06:16:09 PM
#12463   Nice set up for tomorrow cant be many mikekrane 11/20/17 05:36:26 PM
#12462   NP I like the potential here this is John Kent 11/20/17 03:00:29 PM
#12461   Volume grabs the attention of the market. mulally 11/20/17 02:56:44 PM
#12460   John, thanks a lot for your insightful private jtaylor68 11/20/17 02:54:26 PM
#12459   FlutiCare™ will be available OTC with the same John Kent 11/20/17 01:59:20 PM
#12458   Good to see you here future is bright John Kent 11/20/17 01:54:55 PM
#12457   Definitely should bring some more investment into the John Kent 11/20/17 01:40:03 PM
#12456   FlutiCare™ is the first and only nationally branded John Kent 11/20/17 01:20:34 PM
#12455   #44 on BOB and rising great opportunity and John Kent 11/20/17 01:15:34 PM
#12454   Looking real good here dipANDrip 11/20/17 01:09:00 PM
#12453   new out! mikekrane 11/20/17 01:08:24 PM
#12452   great 10q gem clear the 300k note, Dahmer 11/20/17 12:42:28 PM
#12451   dd here is unreal $innv mikekrane 11/20/17 12:37:29 PM
#12450   this is ready to go soon.. people should mikekrane 11/20/17 12:37:14 PM
#12449   This thing is about as coiled as it mulally 11/20/17 12:31:37 PM
#12448   Agreed a nice position and will add learningthetruth 11/20/17 12:24:35 PM
#12447   Innovus Pharma Enters the $11 Billion Glucose Monitoring John Kent 11/20/17 12:21:07 PM
#12446   Thanks great long play here should test 52 John Kent 11/20/17 12:17:36 PM
#12445   Real glad to see that your on INNV jc together 11/20/17 12:06:10 PM
#12444   Exactly true Shawn, thanks for saying that though, gi197845 11/20/17 12:00:30 PM
#12443   Agreed JK...Excellent work and DD here. learningthetruth 11/20/17 11:50:32 AM
#12442   better hurry up, no more cheap shares... mike007 11/20/17 11:50:17 AM
#12441   .08's may be toast for a bit looks BooDog 11/20/17 11:38:21 AM
#12440   Very good read on INNV great potential here. John Kent 11/20/17 11:36:37 AM
#12439   This has so much potential! DEADSKY 11/20/17 11:36:14 AM
#12438   Folks look at the nasal spray market in John Kent 11/20/17 11:32:16 AM
#12437   Its very possible big difference is that fluticare John Kent 11/20/17 11:29:22 AM
#12436   Yes, that is how I calculated it. I gi197845 11/20/17 11:27:42 AM
#12435   A recurring, consistant run would be most welcoming. jbdiver 11/20/17 11:24:17 AM
#12434   Buying on the dip $INNV dipANDrip 11/20/17 11:09:14 AM
#12433   dirt cheap down here im adding a bunch! mikekrane 11/20/17 10:45:31 AM
#12432   I checked on Amazon and Fluticare is currently John Kent 11/20/17 10:41:59 AM
#12431   gi- As long as the SEC can make ShawnP123 11/20/17 10:31:46 AM
#12430   !!! $INNV Investor Starter Guide !!!! John Kent 11/20/17 10:31:19 AM
#12429   gi- trust me your math is wrong. The ShawnP123 11/20/17 10:28:52 AM
#12428   I meant MM's in general, not specifically CDEL gi197845 11/20/17 10:06:30 AM
#12427   I understand your points and will take that gi197845 11/20/17 10:04:13 AM
#12426   Your comment to put in another $22K doesn't ShawnP123 11/20/17 08:59:37 AM
#12425   That article has nothing to do with Nite ShawnP123 11/20/17 08:54:29 AM